NYSE:CRMD
CorMedix Inc Stock News
$5.08
+0.0300 (+0.594%)
At Close: May 21, 2024
CorMedix Inc. Reports Submission of Defencath™ New Drug Application
12:30pm, Wednesday, 08'th Jul 2020
CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease,
COVID-19 claims just one life as 11 further coronavirus cases recorded
05:57pm, Thursday, 25'th Jun 2020
COVID-19 has claimed just one life in the Republic of Ireland and 11 further cases of coronavirus have been recorded in the country. Thursday's update brings the national death toll to 1,727, while 25
Edited Transcript of CRMD earnings conference call or presentation 11-May-20 8:30pm GMT
01:38pm, Tuesday, 09'th Jun 2020
Q1 2020 CorMedix Inc Earnings Call
Is CorMedix Inc. (CRMD) A Good Stock To Buy?
03:41pm, Wednesday, 27'th May 2020
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investmen
CorMedix (CRMD) Moves to Buy: Rationale Behind the Upgrade
04:00pm, Thursday, 21'st May 2020
CorMedix (CRMD) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Analyst Forecasts Just Got A Whole Lot More Bearish On CorMedix Inc. (NYSEMKT:CRMD)
12:48pm, Sunday, 17'th May 2020
Today is shaping up negative for CorMedix Inc. (NYSEMKT:CRMD) shareholders, with the analysts delivering a substantial...
B. Riley FBR Maintains Buy on Cormedix, Raises Price Target to $12
11:45am, Tuesday, 12'th May 2020CorMedix, Inc. (CRMD) CEO Khoso Baluch on Q1 2020 Results - Earnings Call Transcript
01:16am, Tuesday, 12'th May 2020
CorMedix, Inc. (NYSEMKT:CRMD) Q1 2020 Earnings Conference Call May 11, 2020, 16:30 ET Company Participants Daniel Ferry - LifeSci Advisors Khoso Baluch - CEO &a
CorMedix (CRMD) Reports Q1 Loss, Misses Revenue Estimates
11:35pm, Monday, 11'th May 2020
CorMedix (CRMD) delivered earnings and revenue surprises of 8.70% and -48.97%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Cormedix Q1 EPS $(0.210) Beats $(0.230) Estimate, Sales $75.054K Miss $170.000K Estimate
08:15pm, Monday, 11'th May 2020CorMedix Inc. Reports First Quarter 2020 Financial Results and Provides Business Update
08:10pm, Monday, 11'th May 2020
BERKELEY HEIGHTS, N.J., May 11, 2020 -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the.
BRIEF-Cormedix Inc. Announces Appointment Of Chief Financial Officer
12:47pm, Monday, 11'th May 2020
* SAYS MATT DAVID APPOINTED CFO Source text for Eikon: Further company coverage:
CorMedix Inc. Announces Appointment of Chief Financial Officer
12:30pm, Monday, 11'th May 2020
CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseas
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
12:00am, Sunday, 10'th May 2020
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
